HC Wainwright Analysts Decrease Earnings Estimates for TRVI

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Analysts at HC Wainwright reduced their FY2024 EPS estimates for shares of Trevi Therapeutics in a research note issued to investors on Wednesday, December 4th. HC Wainwright analyst O. Livnat now expects that the company will earn ($0.49) per share for the year, down from their previous forecast of ($0.47). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q1 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.49) EPS and FY2028 earnings at ($0.38) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter last year, the company earned ($0.08) EPS.

TRVI has been the subject of several other research reports. Leerink Partnrs raised shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Raymond James assumed coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They set an “outperform” rating and a $9.00 price target for the company. B. Riley reiterated a “buy” rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research report on Monday, October 7th. EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, August 19th. Finally, Leerink Partners assumed coverage on shares of Trevi Therapeutics in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Trevi Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $9.13.

Trevi Therapeutics Stock Performance

TRVI stock opened at $2.68 on Monday. The company has a fifty day moving average price of $2.98 and a 200-day moving average price of $2.91. The company has a market capitalization of $206.00 million, a P/E ratio of -6.09 and a beta of 0.96. Trevi Therapeutics has a 52-week low of $1.10 and a 52-week high of $4.00.

Institutional Investors Weigh In On Trevi Therapeutics

A number of large investors have recently bought and sold shares of TRVI. Logos Global Management LP grew its holdings in shares of Trevi Therapeutics by 27.3% during the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock valued at $8,344,000 after buying an additional 600,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Trevi Therapeutics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after buying an additional 60,249 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Trevi Therapeutics by 38.8% during the second quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock valued at $532,000 after buying an additional 49,884 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Trevi Therapeutics during the first quarter valued at about $47,000. Finally, Ally Bridge Group NY LLC bought a new position in shares of Trevi Therapeutics during the second quarter valued at about $4,395,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.